Biologics Market - Global Forecast 2026-2032

The Biologics Market is projected to reach USD 486.37 Billion in 2026. It is expected to continue growing at a CAGR of 6.61%, reaching USD 719.17 Billion by 2032.

Biologics are reshaping healthcare by translating advances in immunology, cell biology, recombinant DNA technology, and precision medicine into therapies that target disease mechanisms with high specificity. The biologics landscape includes monoclonal antibodies, recombinant proteins, vaccines, blood and plasma products, cell and gene therapies, antibody-drug conjugates, and biosimilars used across oncology, autoimmune disease, rare disease, infectious disease, metabolic disorders, and neurology.

Momentum is supported by sustained regulatory approvals, rising chronic disease burden, expanding biologics manufacturing capacity, and the increasing clinical value of targeted therapies. The U.S. FDA’s Center for Drug Evaluation and Research approved 55 novel drugs in 2023, including biologic products, while biosimilar adoption continues to broaden following the first U.S. biosimilar approval in 2015 and more than 80 biosimilar approvals in Europe since 2006. For industry leaders, competitive advantage increasingly depends on clinical differentiation, scalable bioprocessing, supply chain resilience, regulatory excellence, and evidence generation across the product lifecycle.

Transformative Shifts in the Biologics Landscape

The biologics landscape is undergoing a structural shift from volume-led pharmaceutical models to science-led, outcome-oriented innovation. Monoclonal antibodies remain a core commercial engine, while bispecific antibodies, antibody-drug conjugates, mRNA platforms, cell therapies, and gene therapies are expanding the definition of biological medicines. This transition is increasing demand for specialized capabilities in cell line development, viral vector production, single-use bioprocessing, cold chain logistics, potency testing, and comparability analytics.

At the same time, biosimilars are changing access and pricing dynamics. Regulatory confidence in biosimilar comparability has strengthened in the United States, Europe, Japan, and several emerging markets, encouraging payer adoption and tender-based competition. The industry is also responding to policy pressure around affordability, including U.S. Medicare drug price negotiation under the Inflation Reduction Act and ongoing European initiatives to improve medicine access. These shifts are pushing manufacturers to balance innovation, cost efficiency, patient access, and lifecycle management with greater discipline.

Cumulative Impact of Artificial Intelligence on Biologics

Artificial intelligence is becoming a practical accelerator across biologics discovery, development, manufacturing, and commercialization. In discovery, AI-enabled protein modeling, antibody design, epitope prediction, and developability screening help reduce experimental burden and improve candidate selection. In clinical development, machine learning supports biomarker discovery, patient stratification, trial site selection, protocol optimization, pharmacovigilance signal detection, and real-world evidence analysis.

The cumulative impact of AI is strongest when data quality, governance, and regulatory traceability are embedded from the start. Biologics development generates complex datasets from omics, imaging, process analytics, bioassays, electronic health records, and manufacturing sensors. Organizations that connect these data streams can improve process control, reduce batch failure risk, support quality-by-design strategies, and accelerate regulatory responses. However, AI deployment must be validated, explainable, and aligned with evolving guidance from agencies such as the FDA, EMA, and ICH to ensure patient safety and compliance.

Key Regional Insights Across Global Biologics Markets

North America remains a leading biologics region due to deep biotech funding, advanced clinical trial infrastructure, strong intellectual property protection, and mature regulatory pathways for biologics and biosimilars. The United States anchors the region, supported by FDA review capacity, major biomanufacturing clusters, high specialty medicine utilization, and strong biomedical investment. Canada contributes through clinical research networks, biologics manufacturing investments, and public reimbursement frameworks that increasingly evaluate biosimilars for cost containment.

Europe combines scientific depth with a well-established biosimilar framework. The European Medicines Agency approved the first biosimilar in 2006, and European markets have accumulated extensive real-world experience with switching and tendering. Germany, France, Italy, Spain, and the United Kingdom remain important centers for biologics consumption, clinical research, and advanced therapy development, while European pharmaceutical policy is emphasizing access, supply security, and innovation competitiveness.

Asia-Pacific is advancing rapidly as China, Japan, South Korea, India, Australia, and ASEAN markets expand biologics development and manufacturing. China has accelerated biologics approvals and domestic innovation, India is a major biosimilar and vaccine manufacturing base, Japan maintains rigorous quality and reimbursement systems, and South Korea has built globally competitive biosimilar capabilities. Latin America is led by Brazil and Mexico, where biologics access is expanding through public health systems, private care growth, and local regulatory modernization. The Middle East, particularly GCC countries, is investing in specialty care infrastructure and national health transformation, while Africa is at an earlier stage but gaining attention for vaccine access, cold chain strengthening, regulatory capacity building, and local production initiatives supported by public health priorities.

Key Group Insights for Biologics Strategy

The G7 remains central to biologics innovation because the United States, Japan, Germany, France, the United Kingdom, Italy, and Canada combine advanced research ecosystems, reimbursement capacity, and mature regulatory systems. These markets shape clinical standards, pricing debates, pharmacovigilance expectations, biosimilar policies, and global launch sequencing for biologic therapies.

The European Union is a global reference point for biosimilar regulation, centralized marketing authorization, and health technology assessment coordination. Its policy direction increasingly connects medicine availability, manufacturing resilience, and competitiveness in life sciences. BRICS countries are becoming more influential as China, India, Brazil, Russia, and South Africa expand domestic manufacturing, biosimilar development, vaccine production, and public-sector procurement. China and India are especially important to cost-competitive biologics supply and clinical development scale, while Brazil and South Africa strengthen regional access priorities through public health systems.

ASEAN is emerging as a growth corridor as Indonesia, Thailand, Vietnam, Malaysia, Singapore, and the Philippines expand specialty care access and regulatory harmonization efforts. Singapore is a high-value biomanufacturing and regional headquarters hub, while larger ASEAN markets drive patient access needs across oncology, autoimmune disease, and diabetes care. GCC countries are investing in oncology, diabetes, immunology, and rare disease care through hospital modernization and national health transformation programs. NATO markets overlap significantly with North America and Europe, making them strategically important for supply security, regulatory alignment, emergency preparedness, and resilient pharmaceutical logistics.

Key Country Insights Shaping Biologics Growth

The United States is the most influential biologics market, driven by FDA approvals, high specialty drug use, advanced clinical research, and strong biotech capital formation. Biosimilar uptake has improved in therapeutic areas such as oncology and immunology, although adoption varies by reimbursement design, formulary management, and provider incentives. Canada is focused on access, cost containment, and biosimilar switching policies across provinces, while Mexico is expanding biologics demand through private healthcare, public procurement, and regulatory modernization.

Brazil leads Latin America in biologics consumption and local production ambitions, supported by a large public health system and technology transfer models. The United Kingdom remains a strong life sciences hub with NHS-led biosimilar adoption and advanced therapy initiatives. Germany combines high healthcare spending with strong biopharmaceutical manufacturing and early access pathways, while France emphasizes innovation, reimbursement evaluation, and domestic health sovereignty. Italy and Spain continue to expand biosimilar use through regional procurement and hospital-based prescribing. Russia maintains domestic production priorities and import substitution policies, although geopolitical and supply chain constraints affect international participation.

China has become a major biologics innovation and manufacturing market, supported by regulatory reforms, domestic antibody pipelines, and expanding oncology care. India is a global supplier of vaccines and biosimilars, with competitive manufacturing economics and rising domestic demand. Japan offers a high-quality regulatory environment and strong demand for oncology, immunology, and regenerative medicine. Australia contributes through clinical trials, reimbursement access, and biomedical research, while South Korea is recognized for large-scale biosimilar manufacturing, contract development capabilities, and global biologics exports.

Actionable Recommendations for Biologics Industry Leaders

Industry vendors should prioritize differentiated biologics pipelines supported by strong biomarker strategies, clinically meaningful endpoints, and early payer evidence. Organizations developing monoclonal antibodies, bispecifics, antibody-drug conjugates, cell therapies, gene therapies, vaccines, and biosimilars should build integrated plans that connect target validation, developability, manufacturing scalability, regulatory strategy, and market access from the earliest stages.

Manufacturers should invest in flexible bioprocessing, dual sourcing, raw material risk management, cold chain visibility, and digital quality systems to reduce supply disruptions. AI and automation should be deployed where they can be validated and measured, including process analytics, deviation detection, literature surveillance, clinical trial optimization, and pharmacovigilance workflows. Commercial teams should strengthen real-world evidence generation, physician education, patient support, and biosimilar confidence programs to improve adoption, adherence, and persistence.

Strategic partnerships with contract development and manufacturing organizations, academic centers, diagnostics specialists, healthcare systems, and regional distributors can accelerate geographic expansion. Companies should also monitor regulatory convergence, interchangeability policies, pharmacovigilance requirements, health technology assessment reforms, and drug pricing policies to align launch strategy with local evidence expectations and affordability priorities.

Research Methodology for Biologics Market Intelligence

This executive summary is developed using a structured secondary research approach focused on verified public sources and industry-standard evidence. Key inputs include regulatory agency publications from the FDA, EMA, Health Canada, Japan’s PMDA, China’s NMPA, and other national authorities; policy information from the World Health Organization, OECD, and national health ministries; clinical trial registries; peer-reviewed literature; pharmacovigilance resources; reimbursement documentation; and public biomanufacturing policy updates.

The methodology evaluates biologics through product class, therapeutic area, regulatory pathway, manufacturing model, regional demand indicators, reimbursement environment, and competitive intensity. Insights are triangulated across approval trends, biosimilar adoption evidence, biomanufacturing investments, clinical pipeline signals, public health priorities, and healthcare policy developments. Emphasis is placed on data-backed interpretation rather than unsupported forecasts, ensuring that the analysis remains credible for executives, investors, manufacturers, and market access leaders.

Conclusion: Biologics Leadership Requires Science, Scale, and Access

Biologics are at the center of pharmaceutical innovation, combining scientific precision with substantial clinical and strategic opportunity. The landscape is being reshaped by advanced modalities, biosimilar competition, AI-enabled development, regional manufacturing expansion, and stronger evidence requirements from regulators and payers.

Organizations that combine differentiated science with scalable manufacturing, trusted quality systems, resilient supply chains, and market-specific access strategies will be best positioned to lead. As healthcare systems pursue better outcomes and sustainable spending, biologics developers and manufacturers must prove value through clinical performance, affordability, regulatory confidence, and reliable global supply.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Biologics Market, by Product Type

7.1. Introduction
7.2. Blood Factor Products
7.3. Cell Therapies
7.3.1. CAR-T Therapies
7.3.2. Stem Cell Therapy
7.4. Gene Therapies
7.5. Monoclonal Antibodies
7.6. Recombinant Proteins
7.7. Vaccines

8. Biologics Market, by Technology

8.1. Introduction
8.2. Cell Culture Technology
8.3. Gene Editing Technology
8.3.1. CRISPR
8.3.2. TALENs
8.3.3. Zinc Finger Nucleases
8.4. Hybridoma Technology
8.5. Recombinant DNA Technology

9. Biologics Market, by Route Of Administration

9.1. Introduction
9.2. Intramuscular
9.3. Intravenous
9.4. Subcutaneous

10. Biologics Market, by Presentation Format

10.1. Introduction
10.2. Vials
10.3. Prefilled Syringes
10.4. Cartridges
10.5. Autoinjectors

11. Biologics Market, by Storage Condition

11.1. Introduction
11.2. Refrigerated
11.3. Frozen
11.4. Room Temperature Stable

12. Biologics Market, by Therapeutic Area

12.1. Introduction
12.2. Autoimmune
12.3. Cardiovascular Diseases
12.4. Infectious Diseases
12.5. Metabolic Disorders
12.6. Neurological Disorders
12.7. Oncology

13. Biologics Market, by End User

13.1. Introduction
13.2. Clinics
13.3. Home Healthcare
13.4. Hospitals
13.5. Research Institutes

14. Biologics Market, by Distribution Channel

14.1. Introduction
14.2. Hospital Pharmacy
14.3. Online Channel
14.4. Retail Pharmacy

15. Biologics Market, by Patient Population

15.1. Introduction
15.2. Pediatric
15.3. Adult
15.4. Geriatric

16. Biologics Market, by Region

16.1. Asia-Pacific
16.2. North America
16.3. Latin America
16.4. Europe
16.5. Middle East
16.6. Africa

17. Biologics Market, by Group

17.1. ASEAN
17.2. GCC
17.3. European Union
17.4. BRICS
17.5. G7
17.6. NATO

18. Biologics Market, by Country

18.1. United States
18.2. Canada
18.3. Mexico
18.4. Brazil
18.5. United Kingdom
18.6. Germany
18.7. France
18.8. Russia
18.9. Italy
18.10. Spain
18.11. China
18.12. India
18.13. Japan
18.14. Australia
18.15. South Korea

19. Competitive Landscape

19.1. Market Share Analysis, 2025
19.2. FPNV Positioning Matrix, 2025
19.3. Market Concentration Analysis, 2025
19.3.1. Concentration Ratio (CR)
19.3.2. Herfindahl Hirschman Index (HHI)
19.4. Recent Developments & Impact Analysis, 2025
19.5. Product Portfolio Analysis, 2025
19.6. Benchmarking Analysis, 2025

20. Company Profiles

20.1. AbbVie Inc.
20.2. Ajinomoto Bio-Pharma Services
20.3. Amgen Inc.
20.4. Amneal Pharmaceuticals, Inc.
20.5. AstraZeneca PLC
20.6. Aurobindo Pharma Limited
20.7. Avantor, Inc.
20.8. Baxter International Inc.
20.9. Bayer AG
20.10. Becton, Dickinson and Company
20.11. Biogen Inc.
20.12. BioNTech SE
20.13. Boehringer Ingelheim International GmbH
20.14. Bristol-Myers Squibb Company
20.15. Catalent Inc.
20.16. Celltrion Inc.
20.17. Chugai Pharmaceutical Co., Ltd.
20.18. Cipla Limited
20.19. CSL Limited
20.20. Danaher Corporation
20.21. Eli Lilly and Company
20.22. F. Hoffmann-La Roche AG
20.23. Gilead Sciences Inc.
20.24. GlaxoSmithKline plc
20.25. Johnson & Johnson Services Inc.
20.26. Lonza Group AG
20.27. Merck & Co. Inc.
20.28. Moderna Inc.
20.29. Novartis AG
20.30. Pfizer Inc.
20.31. Samsung Biologics Co. Ltd.
20.32. Sanofi SA
20.33. Takeda Pharmaceutical Company Limited

List of Figures

FIGURE 1. GLOBAL BIOLOGICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BIOLOGICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BIOLOGICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BIOLOGICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BIOLOGICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2025 VS 2032 (%)
FIGURE 13. GLOBAL BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 21. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 27. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 29. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. GLOBAL BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 31. GLOBAL BIOLOGICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

List of Tables

TABLE 1. GLOBAL BIOLOGICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BIOLOGICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL BLOOD FACTOR PRODUCTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL BLOOD FACTOR PRODUCTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL BLOOD FACTOR PRODUCTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CELL THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CELL THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CELL THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CAR-T THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CAR-T THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CAR-T THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL GENE THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL GENE THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL GENE THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL CELL CULTURE TECHNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL CELL CULTURE TECHNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CELL CULTURE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL GENE EDITING TECHNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL GENE EDITING TECHNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL GENE EDITING TECHNOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL CRISPR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CRISPR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CRISPR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL TALENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL TALENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL TALENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ZINC FINGER NUCLEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ZINC FINGER NUCLEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ZINC FINGER NUCLEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL HYBRIDOMA TECHNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL HYBRIDOMA TECHNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL HYBRIDOMA TECHNOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL RECOMBINANT DNA TECHNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL RECOMBINANT DNA TECHNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL RECOMBINANT DNA TECHNOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL VIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL VIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL VIALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PREFILLED SYRINGES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL PREFILLED SYRINGES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL PREFILLED SYRINGES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL CARTRIDGES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL CARTRIDGES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL CARTRIDGES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL AUTOINJECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL AUTOINJECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL AUTOINJECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL REFRIGERATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL REFRIGERATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL REFRIGERATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL FROZEN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL FROZEN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL FROZEN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL ROOM TEMPERATURE STABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL ROOM TEMPERATURE STABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL ROOM TEMPERATURE STABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL AUTOIMMUNE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL AUTOIMMUNE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL AUTOIMMUNE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL ONLINE CHANNEL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL ONLINE CHANNEL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL ONLINE CHANNEL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 148. NORTH AMERICA BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 149. NORTH AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 150. NORTH AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 151. NORTH AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 152. NORTH AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 153. NORTH AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 154. NORTH AMERICA BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 155. NORTH AMERICA BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 156. NORTH AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 157. NORTH AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 158. NORTH AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 159. NORTH AMERICA BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 160. LATIN AMERICA BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 161. LATIN AMERICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 162. LATIN AMERICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 163. LATIN AMERICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 166. LATIN AMERICA BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 167. LATIN AMERICA BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 168. LATIN AMERICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 169. LATIN AMERICA BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 170. LATIN AMERICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 171. LATIN AMERICA BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 172. EUROPE BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 173. EUROPE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 174. EUROPE BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 175. EUROPE BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 176. EUROPE BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 177. EUROPE BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 178. EUROPE BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 179. EUROPE BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 180. EUROPE BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 181. EUROPE BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 182. EUROPE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 183. EUROPE BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 184. MIDDLE EAST BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 185. MIDDLE EAST BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 186. MIDDLE EAST BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 187. MIDDLE EAST BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 188. MIDDLE EAST BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 190. MIDDLE EAST BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 191. MIDDLE EAST BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 192. MIDDLE EAST BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 193. MIDDLE EAST BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 194. MIDDLE EAST BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 195. MIDDLE EAST BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 196. AFRICA BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 197. AFRICA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 198. AFRICA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 199. AFRICA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 200. AFRICA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 201. AFRICA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 202. AFRICA BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 203. AFRICA BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 204. AFRICA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 205. AFRICA BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 206. AFRICA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 207. AFRICA BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 208. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 209. ASEAN BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 210. ASEAN BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 211. ASEAN BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 212. ASEAN BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 213. ASEAN BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 214. ASEAN BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 215. ASEAN BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 216. ASEAN BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 217. ASEAN BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 218. ASEAN BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 219. ASEAN BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 220. ASEAN BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 221. GCC BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 222. GCC BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 223. GCC BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 224. GCC BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 225. GCC BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 226. GCC BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 227. GCC BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 228. GCC BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 229. GCC BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 230. GCC BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 231. GCC BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 232. GCC BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 245. BRICS BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 246. BRICS BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 247. BRICS BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 248. BRICS BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 249. BRICS BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 250. BRICS BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 251. BRICS BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 252. BRICS BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 253. BRICS BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 254. BRICS BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 255. BRICS BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 256. BRICS BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 257. G7 BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 258. G7 BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 259. G7 BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 260. G7 BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 261. G7 BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 262. G7 BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 263. G7 BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 264. G7 BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 265. G7 BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 266. G7 BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 267. G7 BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 268. G7 BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 269. NATO BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 270. NATO BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 271. NATO BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 272. NATO BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 273. NATO BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 274. NATO BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 275. NATO BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 276. NATO BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 277. NATO BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 278. NATO BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 279. NATO BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 280. NATO BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 281. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 282. UNITED STATES BIOLOGICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 283. UNITED STATES BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 284. UNITED STATES BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 285. UNITED STATES BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 286. UNITED STATES BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 287. UNITED STATES BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 288. UNITED STATES BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 289. UNITED STATES BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 290. UNITED STATES BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 291. UNITED STATES BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 292. UNITED STATES BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 293. UNITED STATES BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 294. CANADA BIOLOGICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 295. CANADA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 296. CANADA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 297. CANADA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 298. CANADA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 299. CANADA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 300. CANADA BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 301. CANADA BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 302. CANADA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 303. CANADA BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 304. CANADA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 305. CANADA BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 306. MEXICO BIOLOGICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 307. MEXICO BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 308. MEXICO BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 309. MEXICO BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 310. MEXICO BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 311. MEXICO BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 312. MEXICO BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 313. MEXICO BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 314. MEXICO BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 315. MEXICO BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 316. MEXICO BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 317. MEXICO BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 318. BRAZIL BIOLOGICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 319. BRAZIL BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 320. BRAZIL BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 321. BRAZIL BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 322. BRAZIL BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 323. BRAZIL BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 324. BRAZIL BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 325. BRAZIL BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 326. BRAZIL BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 327. BRAZIL BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 328. BRAZIL BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 329. BRAZIL BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 330. UNITED KINGDOM BIOLOGICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 331. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 332. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 333. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 334. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 335. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 336. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 337. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 338. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 339. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 340. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 341. UNITED KINGDOM BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 342. GERMANY BIOLOGICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 343. GERMANY BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 344. GERMANY BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 345. GERMANY BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 346. GERMANY BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 347. GERMANY BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 348. GERMANY BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 349. GERMANY BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 350. GERMANY BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 351. GERMANY BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 352. GERMANY BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 353. GERMANY BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 354. FRANCE BIOLOGICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 355. FRANCE BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 356. FRANCE BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 357. FRANCE BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 358. FRANCE BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 359. FRANCE BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 360. FRANCE BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 361. FRANCE BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 362. FRANCE BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 363. FRANCE BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 364. FRANCE BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 365. FRANCE BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 366. RUSSIA BIOLOGICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 367. RUSSIA BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 368. RUSSIA BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 369. RUSSIA BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 370. RUSSIA BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 371. RUSSIA BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 372. RUSSIA BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 373. RUSSIA BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 374. RUSSIA BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 375. RUSSIA BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 376. RUSSIA BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 377. RUSSIA BIOLOGICS MARKET SIZE, BY PATIENT POPULATION, 2017-2032 (USD MILLION)
TABLE 378. ITALY BIOLOGICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 379. ITALY BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 380. ITALY BIOLOGICS MARKET SIZE, BY CELL THERAPIES, 2017-2032 (USD MILLION)
TABLE 381. ITALY BIOLOGICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 382. ITALY BIOLOGICS MARKET SIZE, BY GENE EDITING TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 383. ITALY BIOLOGICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 384. ITALY BIOLOGICS MARKET SIZE, BY PRESENTATION FORMAT, 2017-2032 (USD MILLION)
TABLE 385. ITALY BIOLOGICS MARKET SIZE, BY STORAGE CONDITION, 2017-2032 (USD MILLION)
TABLE 386. ITALY BIOLOGICS MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 387. ITALY BIOLOGICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABL

Companies Mentioned

AbbVie Inc.
Ajinomoto Bio-Pharma Services
Amgen Inc.
Amneal Pharmaceuticals, Inc.
AstraZeneca PLC
Aurobindo Pharma Limited
Avantor, Inc.
Baxter International Inc.
Bayer AG
Becton, Dickinson and Company
Biogen Inc.
BioNTech SE
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Catalent Inc.
Celltrion Inc.
Chugai Pharmaceutical Co., Ltd.
Cipla Limited
CSL Limited
Danaher Corporation
Eli Lilly and Company
F. Hoffmann-La Roche AG
Gilead Sciences Inc.
GlaxoSmithKline plc
Johnson & Johnson Services Inc.
Lonza Group AG
Merck & Co. Inc.
Moderna Inc.
Novartis AG
Pfizer Inc.
Samsung Biologics Co. Ltd.
Sanofi SA
Takeda Pharmaceutical Company Limited

Table Information

Report Attribute	Details
No. of Pages	198
Published	August 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 486.37 Billion
Forecasted Market Value ( USD ) by 2032	$ 719.17 Billion
Compound Annual Growth Rate	6.6%
Regions Covered	Global
No. of Companies Mentioned	34

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3184EUR$3,545USD£2,720GBP €3538EUR$3,939USD£3,022GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4817EUR$5,363USD£4,115GBP €5352EUR$5,959USD£4,572GBP

Transformative Shifts in the Biologics Landscape

Cumulative Impact of Artificial Intelligence on Biologics

Key Regional Insights Across Global Biologics Markets

Key Group Insights for Biologics Strategy

Key Country Insights Shaping Biologics Growth

Actionable Recommendations for Biologics Industry Leaders

Research Methodology for Biologics Market Intelligence

Conclusion: Biologics Leadership Requires Science, Scale, and Access

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Biologics Contract Manufacturing Market - Global Forecast 2026-2032

Biologics Contract Development & Manufacturing Organization Market - Global Forecast 2026-2032

Biologics Contract Development - Global Strategic Business Report

Biologics - Global Strategic Business Report

Spine Biologics Market Report by Product, Surgery Type, End User, and Region 2026-2034